SPEVIGO
(Spevigo)PreclinicalSmall molecule
Boehringer IngelheimSPEVIGO is one of 12 small molecule programs targeting Generalized Pustular Psoriasis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Generalized Pustular Psoriasis
#DrugCompanyPhaseTrials
1Taltz
Eli LillyApproved
Spevigo
Boehringer IngelheimApproved
Tremfya
Johnson & JohnsonPhase 3
Skyrizi
AbbViePhase 3
Humira
CCelltrion
Phase 3
JNJ-77242113
Johnson & JohnsonPhase 3
TAK-279
TakedaPhase 3
Imsidolimab
VVanda Pharmaceuticals
Phase 2
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Sep 1, 2022
SPEVIGO
BLA BLA761244
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spevigo. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company